$247.65
0.00% yesterday
NYSE, May 13, 10:10 pm CET
ISIN
US7611521078
Symbol
RMD

ResMed Stock price

$247.65
+33.12 15.44% 1M
+12.21 5.19% 6M
+18.96 8.29% YTD
+29.76 13.66% 1Y
+50.79 25.80% 3Y
+83.28 50.67% 5Y
+192.17 346.38% 10Y
NYSE, Closing price Tue, May 13 2025
-0.01 0.00%
ISIN
US7611521078
Symbol
RMD
Sector

Key metrics

Market capitalization $36.31b
Enterprise Value $36.22b
P/E (TTM) P/E ratio 27.81
EV/FCF (TTM) EV/FCF 23.09
EV/Sales (TTM) EV/Sales 7.21
P/S ratio (TTM) P/S ratio 7.23
P/B ratio (TTM) P/B ratio 6.56
Dividend yield 0.86%
Last dividend (FY25) $2.12
Revenue growth (TTM) Revenue growth 9.54%
Revenue (TTM) Revenue $5.02b
EBIT (operating result TTM) EBIT $1.61b
Free Cash Flow (TTM) Free Cash Flow $1.57b
Cash position $932.71m
EPS (TTM) EPS $8.91
P/E forward 26.58
P/S forward 7.09
EV/Sales forward 7.07
Short interest 7.40%
Show more

Is ResMed a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,793 stocks worldwide.

ResMed Stock Analysis

Unlock Scores for Free

Analyst Opinions

29 Analysts have issued a ResMed forecast:

21x Buy
72%
7x Hold
24%
1x Sell
3%

Analyst Opinions

29 Analysts have issued a ResMed forecast:

Buy
72%
Hold
24%
Sell
3%

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
5,022 5,022
10% 10%
100%
- Direct Costs 2,116 2,116
2% 2%
42%
2,906 2,906
16% 16%
58%
- Selling and Administrative Expenses 752 752
8% 8%
15%
- Research and Development Expense 326 326
7% 7%
6%
1,828 1,828
21% 21%
36%
- Depreciation and Amortization 216 216
0% 0%
4%
EBIT (Operating Income) EBIT 1,612 1,612
25% 25%
32%
Net Profit 1,313 1,313
37% 37%
26%

In millions USD.

Don't miss a Thing! We will send you all news about ResMed directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ResMed Stock News

Positive
Seeking Alpha
12 days ago
My Top 15 High-Growth Dividend stocks for April 2025 outperformed SPY and VIG, posting a 0.12% gain versus SPY's -0.87% and VIG's -1.53%. Year-to-date, the Top 15 list returned -0.36%, outperforming VIG's -2.46% and SPY's -5.40%, aiming for a long-term 12% return. The May 2025 Top 15 stocks offer a 1.33% average dividend yield with a 21.25% 5-year dividend growth rate and are 29% undervalued.
Neutral
GlobeNewsWire
13 days ago
Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers Acquisition supports Resmed's growth in virtual care, expands access to diagnosis, and enhances the digital experience for patients and providers
Positive
Seeking Alpha
20 days ago
ResMed is a dominant player in healthcare devices with strong margins, recurring revenues, and a near-monopoly, offering a compelling mix of value and growth. The company continually invests in R&D, enhancing its product portfolio, customer experience, and expanding into new markets, justifying its premium share price. Concerns about GLP-1 drugs reducing ResMed's market are countered by data su...
More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office United States
CEO Mick Farrell
Employees 9,980
Founded 1989
Website www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today